Document Detail


A review of secondary coronary prevention with dipyridamole and aspirin.
MedLine Citation:
PMID:  2082486     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A large number of placebo-controlled trials of antiplatelet drugs have been carried out. A summary of the results of AMIS, CDP, ISIS-2, PARIS I and II and the Antiplatelet Trialists' Collaboration is presented. It is concluded that two fatal events and three non-fatal events will be averted for every 100 patients given a 2-year course of antiplatelet agents, starting promptly after myocardial infarction.
Authors:
C R Prentice
Related Documents :
18473866 - Safety and efficacy of bivalirudin in acute coronary syndromes.
9262116 - Current status on new anticoagulant and antithrombotic drugs and devices.
11316916 - Benefit of adp receptor antagonists in atherothrombotic patients: new evidence.
15957976 - Clinical use of enoxaparin in the management of non-st segment elevation acute coronary...
8869016 - Description of patients undergoing high risk angioplasty. analyses of various databases.
24217126 - Acute myocardial infarction after prednisolone administration for the treatment of anap...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Thrombosis research. Supplement     Volume:  12     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res. Suppl.     Publication Date:  1990  
Date Detail:
Created Date:  1991-05-09     Completed Date:  1991-05-09     Revised Date:  2008-02-28    
Medline Journal Info:
Nlm Unique ID:  8309239     Medline TA:  Thromb Res Suppl     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  43-9     Citation Subset:  IM    
Affiliation:
University Department of Medicine, General Infirmary, Leeds, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aspirin / therapeutic use*
Clinical Trials as Topic
Dipyridamole / therapeutic use*
Drug Therapy, Combination
Humans
Myocardial Infarction / drug therapy*
Platelet Aggregation Inhibitors / therapeutic use*
Recurrence
Risk Factors
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 58-32-2/Dipyridamole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dipyridamole combined with anticoagulant in prevention of early postoperative thromboembolism after ...
Next Document:  Effect of dipyridamole and aspirin on vein graft patency after coronary bypass operations.